Verona Pharma

NASDAQ: VRNA · Real-Time Price · USD
84.14
2.94 (3.62%)
At close: Jun 02, 2025, 3:59 PM
84.00
-0.16%
After-hours: Jun 02, 2025, 07:45 PM EDT

Verona Pharma Statistics

Share Statistics

Verona Pharma has 84.98M shares outstanding. The number of shares has increased by 734.97% in one year.

Shares Outstanding 84.98M
Shares Change (YoY) 734.97%
Shares Change (QoQ) 727.32%
Owned by Institutions (%) 10.53%
Shares Floating n/a
Failed to Deliver (FTD) Shares 2,014
FTD / Avg. Volume 0.15%

Short Selling Information

The latest short interest is 8.07M, so 9.49% of the outstanding shares have been sold short.

Short Interest 8.07M
Short % of Shares Out 9.49%
Short % of Float 9.9%
Short Ratio (days to cover) 6.27

Valuation Ratios

The PE ratio is -21.84 and the forward PE ratio is 89.02. Verona Pharma's PEG ratio is -0.11.

PE Ratio -21.84
Forward PE 89.02
PS Ratio 89.56
Forward PS 4.8
PB Ratio 18.51
P/FCF Ratio -30.84
PEG Ratio -0.11
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Verona Pharma.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 10.63, with a Debt / Equity ratio of 0.6.

Current Ratio 10.63
Quick Ratio 10.48
Debt / Equity 0.6
Debt / EBITDA -0.86
Debt / FCF -1
Interest Coverage -6.57

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $202,291.87
Profits Per Employee $-829,751.2
Employee Count 209
Asset Turnover 0.09
Inventory Turnover 0.41

Taxes

Income Tax 10.29M
Effective Tax Rate -6.31%

Stock Price Statistics

The stock price has increased by 572.49% in the last 52 weeks. The beta is 0.2, so Verona Pharma's price volatility has been higher than the market average.

Beta 0.2
52-Week Price Change 572.49%
50-Day Moving Average 65.99
200-Day Moving Average 48.62
Relative Strength Index (RSI) 70.84
Average Volume (20 Days) 1,358,606

Income Statement

In the last 12 months, Verona Pharma had revenue of 42.28M and earned -173.42M in profits. Earnings per share was -2.16.

Revenue 42.28M
Gross Profit 39.7M
Operating Income -154.63M
Net Income -173.42M
EBITDA -142.19M
EBIT -139.59M
Earnings Per Share (EPS) -2.16
Full Income Statement

Balance Sheet

The company has 399.76M in cash and 122.7M in debt, giving a net cash position of 277.06M.

Cash & Cash Equivalents 399.76M
Total Debt 122.7M
Net Cash 277.06M
Retained Earnings -562.4M
Total Assets 525.94M
Working Capital 444.48M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -122.2M and capital expenditures 0, giving a free cash flow of -122.78M.

Operating Cash Flow -122.2M
Capital Expenditures n/a
Free Cash Flow -122.78M
FCF Per Share -0.19
Full Cash Flow Statement

Margins

Gross margin is 93.89%, with operating and profit margins of -365.73% and -410.18%.

Gross Margin 93.89%
Operating Margin -365.73%
Pretax Margin -385.84%
Profit Margin -410.18%
EBITDA Margin -336.31%
EBIT Margin -365.73%
FCF Margin -290.41%

Dividends & Yields

VRNA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for VRNA is $72, which is -11.3% lower than the current price. The consensus rating is "Strong Buy".

Price Target $72
Price Target Difference -11.3%
Analyst Consensus Strong Buy
Analyst Count 5
Stock Forecasts

Scores

Altman Z-Score 10.94
Piotroski F-Score 4